SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Dhingra Kapil
(Last) (First) (Middle)
C/O LAVA THERAPEUTICS N.V.
YALELAAN 62
(Street)
UTRECHT P7 3584 CM
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2025 		3. Issuer Name and Ticker or Trading Symbol
LAVA Therapeutics NV [ LVTX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares 30,000 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Options (Right to Buy) (1) 03/02/2031 Common Shares 104,754 $8.14(2) D
Share Options (Right to Buy) (3) 03/02/2031 Common Shares 102,986 $8.14(2) D
Share Options (Right to Buy) (4) 12/20/2031 Common Shares 20,000 $5.1 D
Share Options (Right to Buy) (4) 12/22/2032 Common Shares 20,000 $3.64 D
Share Options (Right to Buy) (5) 01/18/2034 Common Shares 33,390 $1.59 D
Explanation of Responses:
1. The shares underlying the option vest in 48 equal monthly installments beginning on February 26, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
2. Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 7.84 euros per share.
3. The shares underlying the option vest in 48 equal monthly installments beginning on March 17, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
4. Fully vested and immediately exercisable.
5. 100% of the shares underlying the option will vest on January 19, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.
/s/ Amy Garabedian, Attorney-in-Fact 01/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.